On Monday, BridgeBio Pharma Inc (NASDAQ: BBIO) was -6.15% drop from the session before settling in for the closing price of $78.24. A 52-week range for BBIO has been $27.79 – $78.54.
Annual sales at Healthcare sector company slipped by -3.04% over the past five years. When this article was written, the company’s average yearly earnings per share was at -21.90%. With a float of $164.63 million, this company’s outstanding shares have now reached $192.63 million.
BridgeBio Pharma Inc (BBIO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward BridgeBio Pharma Inc stocks. The insider ownership of BridgeBio Pharma Inc is 14.57%, while institutional ownership is 87.87%. The most recent insider transaction that took place on Dec 15 ’25, was worth 2,239,902. In this transaction Chief Executive Officer of this company sold 30,011 shares at a rate of $74.64, taking the stock ownership to the 228,776 shares. Before that another transaction happened on Dec 15 ’25, when Company’s Director proposed sale 30,011 for $75.15, making the entire transaction worth $2,255,327.
BridgeBio Pharma Inc (BBIO) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.37 earnings per share (EPS) during the time that was less than consensus figure (set at -1.09) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
You can see what BridgeBio Pharma Inc (BBIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.57 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 1.88 million, a negative change from its year-to-date volume of 2.72 million. As of the previous 9 days, the stock’s Stochastic %D was 58.45%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 83.75%, which indicates a significant increase from 21.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.37 in the past 14 days, which was higher than the 2.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $69.52, while its 200-day Moving Average is $50.07. Nevertheless, the first resistance level for the watch stands at $77.34 in the near term. At $81.26, the stock is likely to face the second major resistance level. The third major resistance level sits at $83.93. If the price goes on to break the first support level at $70.74, it is likely to go to the next support level at $68.07. Assuming the price breaks the second support level, the third support level stands at $64.15.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are 192,709K outstanding shares of the company, which has a market capitalization of 14.15 billion. As of now, sales total 221,900 K while income totals -535,760 K. Its latest quarter income was 120,700 K while its last quarter net income were -182,740 K.
